Mary Wilson
Well-known member
Accepted Date: 8 December 2022
Published December 13, 2022
DOI:https://doi.org/10.1016/j.cell.2022.12.018
Qian Wang [SUP]8 [/SUP]Sho Iketani [SUP]8 [/SUP]Zhiteng Li [SUP]8 [/SUP]Aubree Gordon Lihong Liu David D. Ho [SUP]7 [/SUP]Show all authors
Highlights
The BQ and XBB subvariants of SARS-CoV-2 Omicron are now rapidly expanding, possibly due to altered antibody evasion properties deriving from their additional spike mutations. Here, we report that neutralization of BQ.1, BQ.1.1, XBB, and XBB.1 by sera from vaccinees and infected persons was markedly impaired, including sera from individuals boosted with a WA1/BA.5 bivalent mRNA vaccine. Titers against BQ and XBB subvariants were lower by 13-81-fold and 66-155-fold, respectively, far beyond what had been observed to date. Monoclonal antibodies capable of neutralizing the original Omicron variant were largely inactive against these new subvariants, and the responsible individual spike mutations were identified. These subvariants were found to have similar ACE2-binding affinities as their predecessors. Together, our findings indicate that BQ and XBB subvariants present serious threats to current COVID-19 vaccines, render inactive all authorized antibodies, and may have gained dominance in the population because of their advantage in evading antibodies.
https://www.cell.com/cell/fulltext/S0092-8674(22)01531-8
Published December 13, 2022
DOI:https://doi.org/10.1016/j.cell.2022.12.018
Qian Wang [SUP]8 [/SUP]Sho Iketani [SUP]8 [/SUP]Zhiteng Li [SUP]8 [/SUP]Aubree Gordon Lihong Liu David D. Ho [SUP]7 [/SUP]Show all authors
Highlights
- •
BQ.1, BQ.1.1, XBB, and XBB.1 are the most resistant SARS-CoV-2 variants to date - •
Serum neutralization was markedly reduced, including with the bivalent booster - •
All clinical monoclonal antibodies were rendered inactive against these variants - •
The ACE2 affinity of these variants were similar to their parental strains
The BQ and XBB subvariants of SARS-CoV-2 Omicron are now rapidly expanding, possibly due to altered antibody evasion properties deriving from their additional spike mutations. Here, we report that neutralization of BQ.1, BQ.1.1, XBB, and XBB.1 by sera from vaccinees and infected persons was markedly impaired, including sera from individuals boosted with a WA1/BA.5 bivalent mRNA vaccine. Titers against BQ and XBB subvariants were lower by 13-81-fold and 66-155-fold, respectively, far beyond what had been observed to date. Monoclonal antibodies capable of neutralizing the original Omicron variant were largely inactive against these new subvariants, and the responsible individual spike mutations were identified. These subvariants were found to have similar ACE2-binding affinities as their predecessors. Together, our findings indicate that BQ and XBB subvariants present serious threats to current COVID-19 vaccines, render inactive all authorized antibodies, and may have gained dominance in the population because of their advantage in evading antibodies.
https://www.cell.com/cell/fulltext/S0092-8674(22)01531-8
